secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001193125-23-263647
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex reports pepinemab significantly reduces GFAP biomarker in Huntington's disease; presented at CTAD.
--------------------------------------------------------------------------------

- Pepinemab reduced plasma GFAP levels in HD patients vs placebo using highly sensitive S-PLEX immunoassay.
- Data from podium presentation at CTAD Conference in Boston on October 26, 2023.
- Prior phase 2 HD trial showed pepinemab prevented decline in glucose uptake and slowed cognitive decline (HD-CAB).
- Ongoing SIGNAL-AD trial in Alzheimer's; last patient to complete 12-month treatment expected by June 2024.
- Company sees pepinemab as potential alternative or complement to anti-Aβ antibodies for Alzheimer's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523263647/0001193125-23-263647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523263647/d550531d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-263647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer